Akcea Therapeutics (NASDAQ:AKCA) announced its quarterly earnings results on Monday. The company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07, Briefing.com reports. Akcea Therapeutics had a negative net margin of 192.97% and a negative return on equity of 58.32%. The firm had revenue of $19.24 million during the quarter, compared to the consensus estimate of $20.52 million. During the same period last year, the firm earned ($0.33) EPS. The business’s quarterly revenue was up 94.3% compared to the same quarter last year.
Shares of Akcea Therapeutics stock traded down $0.23 on Wednesday, hitting $27.00. 8,082 shares of the company traded hands, compared to its average volume of 434,221. The stock has a market cap of $2.17 billion, a P/E ratio of -12.16 and a beta of 2.57. Akcea Therapeutics has a 12-month low of $15.20 and a 12-month high of $40.75.
Several research analysts have commented on AKCA shares. Needham & Company LLC started coverage on shares of Akcea Therapeutics in a report on Tuesday, September 18th. They issued a “buy” rating and a $45.00 price target for the company. Zacks Investment Research raised shares of Akcea Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 30th. ValuEngine cut shares of Akcea Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Stifel Nicolaus raised their price objective on shares of Akcea Therapeutics from $25.00 to $31.00 and gave the company a “hold” rating in a research report on Tuesday, September 25th. Finally, Cowen restated a “hold” rating on shares of Akcea Therapeutics in a research report on Sunday, September 2nd. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Akcea Therapeutics has a consensus rating of “Hold” and an average price target of $38.20.
TRADEMARK VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/11/07/akcea-therapeutics-akca-announces-quarterly-earnings-results.html.
About Akcea Therapeutics
Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.
Featured Story: Balance Sheet
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.